Due to the widespread use of screening tests, the incidence of cervical cancer has decreased significantly. Precancerous lesions can be identified and removed before they become cancerous. In 2010, approximately 12,200 patients were diagnosed with cervical cancer in the United States. Around 4,210 people will die from this disease.
Screening tests include traditional swabs or liquid cytology with or without DNA testing for HPV (human papillomavirus). For the best information about cancer screening in Kenya, visit jacarandamaternity.co.ke/cervical-cancer.
The current recommendations from the American College of Obstetricians and Gynecologists for normal-risk women are as follows:
1) Blur Board starts at 21
2) <30 years: every 2 years
3) > 30 years: every 3 years
4) Stop screening at age 65-70 after 3 normal tests in the past 10 years.
Screening is more common in high-risk women. High-risk conditions include a history of cervical cancer, exposure to DES (diethylstilbestrol) in the fetus, and impaired immune system (from transplant drugs, chemotherapy, steroids, or HIV). Please note that the screening recommendations above apply to "asymptomatic" patients.
If you think you are experiencing new symptoms such as unusual bleeding, excessive blood flow, pelvic pain, pain when urinating, etc., discuss this with your doctor. With the recent development of vaccines, cervical cancer is now a potentially preventable disease.